New antibody drug targets Hard-to-Treat cancers in first human trial

NCT ID NCT06636435

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called CBA-1205 in people with advanced solid tumors (like liver cancer or melanoma) that have not responded to other treatments. The main goal is to check the drug's safety and find the best dose. About 66 participants will receive the drug, and researchers will monitor side effects and measure how the body processes the drug.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

childhood malignant neoplasm hepatocellular carcinoma melanoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Kanagawa Cancer Center

    RECRUITING

    Yokohama, Kanagawa, 241-8515, Japan

  • National Cancer Center Hospital

    RECRUITING

    Chūō, Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East

    RECRUITING

    Kashiwa, Chiba, 277-8577, Japan

  • Niigata University Medical and Dental Hospital

    RECRUITING

    Niigata, Niigata, 951-8520, Japan

  • University of Yamanashi Hospital

    RECRUITING

    Chūō, Yamanashi, 409-3898, Japan